Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206969 | 0.83 | PTPN11 (0.46) | — | |
| SCHEMBL20206975 | 0.81 | PTPN11 (0.44) | L3MBTL1 | |
| SCHEMBL20206972 | 0.80 | KDM4E (0.47) | HPGDLMNAKMT2A | |
| SCHEMBL20206970 | 0.79 | TLR2 (0.45) | SMN1; SMN2CA2 | |
| SCHEMBL20187628 | 0.78 | PTPN11 (0.68) | HPGDALDH1A1SMN1; SMN2LMNATTR | |
| SCHEMBL6567318 | 0.78 | HDAC6 (0.61) | HPGDALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL20207162 | 0.77 | HDAC2 (0.60) | HPGDALDH1A1CYP2C19LMNAHDAC2 | |
| SCHEMBL20207003 | 0.75 | PTPN11 (0.49) | — | |
| SCHEMBL20206986 | 0.74 | PTPN11 (0.68) | — | |
| SCHEMBL2915318 | 0.72 | HDAC6 (0.74) | HPGDALDH1A1SMN1; SMN2LMNAHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544952-B1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIV ANTWERPEN (BE) | 2024-11-06 | — | — | EP | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) | 2020-08-11 | — | — | US | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096088-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284130-A1 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | ATG4B, ATG7, ATG4A | HPGD 2238/4885ALDH1A1 3918/4885CYP2C19 2589/4885 |
| US-10738002-B2 | Halogenated benzotropolones as ATG4B inhibitors | ATG4B, ATG7, BECN1 | HPGD 1656/4885ALDH1A1 3405/4885CYP2C19 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.